Search Results
Your search for what matches 6155 pages
Showing 1951 - 2000Role of Race, Ethnicity, and Region in Mortality Among Pediatric Patients With Cancer Admitted to the ICU
Black and Hispanic children admitted to pediatric intensive care units for cancer treatment have significantly higher death rates than non-Hispanic white patients, according to findings from a study published by Laurens et al in Pediatric Critical Care Medicine. Nationwide, 8.5% of black and 8.1%...
News Highlights for Patients With Cancer From the ASCO20 Virtual Scientific Program
Direct your patients to the award-winning Cancer.Net Blog (www.cancer.net/blog) to stay up to date on the latest research and learn what it means for their care and treatment. This summer, the Cancer.Net Blog will also offer continuing coverage from the ASCO20 Virtual Scientific Program with the...
The Power of mCODE
ASCO Chief Executive Officer Clifford A. Hudis, MD, FACP, FASCO, hosts the ASCO in Action Podcast, which focuses on policy and practice issues affecting providers and patients. An excerpt of a recent episode is shared below; it has been edited for length and clarity. Listen to the full podcast on...
Veliparib Plus Chemotherapy Shows Antitumor Activity in Front-Line Treatment of Ovarian Cancer, but Is It Enough?
An updated analysis of the phase III VELIA/GOG-3005 trial, presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series,1 suggested synergy between the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib and platinum chemotherapy in the...
Expert Point of View: Susan Domchek, MD, and Aditya Bardia, MD, MPH
“PARP inhibitors are a major advance in the treatment of BRCA1- and BRCA2-mutated tumors, including prostate, breast, ovarian, and pancreatic cancers,” said discussant Susan Domchek, MD, Director of the Basser Center for BRCA at Penn Medicine’s Abramson Cancer Center in Philadelphia. Nevertheless,...
Expert Point of View: David G. Huntsman, MD
Study discussant David G. Huntsman, MD, Founder and Chief Medical Officer of Contextual Genomics, noted the positive predictive value of DETECT-A was 19%, which increased to 41% with the addition of positron-emission tomography/computed tomography. He pointed out that most cancers detected by the...
When Is It Time to Pass?
Assisted suicide gets a lot of press, as if it were a new event. About 20 to 30 years ago, it was ever present but neither defined nor acknowledged. When patients left the hospital for what they and I believed to be the last time, I did one or both of two things: gave them my home number or, if...
My Future Is Doled Out in Increments of 6 Months
In the fall of 2015, I was looking forward to a trip to Florida for a visit with my daughter and her family, along with a little relaxation. The evening before the trip, I experienced some abdominal pain that my wife, Angela, and I thought might be appendicitis. Concerned the problem could...
Cognitive Impairment in Women Treated for Early Breast Cancer: Chemoendocrine Adjuvant Therapy vs Endocrine Therapy Alone
Women with early-stage breast cancer who received adjuvant chemoendocrine therapy reported greater cognitive impairment at 3 and 6 months than women receiving adjuvant endocrine therapy alone, according to the results from a subgroup of women participating in the TAILORx trial.1 By 12 months, the...
The Gambler
The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...
Addition of CD38-Directed Antibody Isatuximab to Multiple Myeloma Armamentarium
The treatment approaches to multiple myeloma have significantly changed over the past decade with the introduction of many new active agents. Among them, the monoclonal antibodies have been one of the most exciting advances in myeloma, complementing their success in other hematologic cancers. In...
A Nobel Laureate’s Road to Research Is Not Without Challenges
The 2019 Nobel Prize for Physiology and Medicine was jointly awarded to three researchers. Their discoveries paved the way for promising new strategies to treat anemia, cancer, and many other diseases. One of the three Nobel Laureates is William G. Kaelin, Jr, MD, who continues his research at his...
An Early Interest in Cancer Immunology Inspires a Life’s Work in Melanoma
F. Stephen Hodi, MD, Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women’s Cancer Center, was born in Framingham and grew up in the town of Acton, a western suburb of Boston. “My dad was an engineer, and I was influenced by puzzle-solving and using...
ASCO’s President Aims to Ensure Equitable Cancer Care for Every Patient
The desire to pursue a career in medicine took root when Lori J. Pierce, MD, FASTRO, FASCO, was a young child visiting family in segregated Ahoskie, North Carolina. She witnessed firsthand the impact the town’s lone African American family physician had on the community. When it came time to...
Tribute to Bernard Fisher, MD
Bernard Fisher, MD, who died on October 16, 2019, at the age of 101, is recognized today for his groundbreaking research in breast cancer, which ultimately ended the standard practice of performing the Halsted radical mastectomy, a treatment that had been in place for more than 75 years. His...
Renowned Researcher and Surgeon Helps to Transform Treatment of Breast Cancer
Although ‘paradigm shifts’ are frequently referenced in oncology, these are really few and far between. They occur when new data either partially invalidate previously accepted theory or are at complete odds with the existing paradigm. Moving away from the Halsted radical mastectomy, a standard of ...
Internationally Regarded Cancer Immunologist Did Not Stray Far From Home
Internationally recognized immune-oncology melanoma expert Jedd D. Wolchok, MD, PhD, FASCO, was born and reared in Staten Island, not far from where he would shape his noted career at Memorial Sloan Kettering Cancer Center (MSK) in New York, New York. “I went to Princeton University and, during my ...
Expert in Clinical Trial Methodology Makes His Mark in Genitourinary Cancer
In 2019, at the ASCO Annual Meeting, Ian Tannock, MD, PhD, DSc, FASCO, was honored with the Allen S. Lichter Visionary Award for his contributions to the fields of genitourinary and breast cancers as well as his efforts to optimize clinical trial design. The title of his lecture was “Clinical...
Love of Science, Passion for Research, and Belief in the Power of the Immune System
Steven A. Rosenberg, MD, PhD, FASCO, knew from the start of his medical career that if treatments for cancer were to become curative, research in new therapies would have to move away from the mainstay one-size-fits-all approach of systemic chemotherapy to an innovative, personalized strategy that ...
Early Local Therapy Did Not Extend Survival in Patients With Newly Diagnosed Metastatic Breast Cancer
Women who present at diagnosis with advanced breast cancer have faced an unanswered question: will local therapy, consisting of surgery and radiation to the tumor in the breast, prolong survival compared to the traditional treatment of systemic treatment alone? Now, data from the randomized phase...
Geriatric Assessment–Driven Intervention Benefits Older Adults With Cancer
Geriatric assessment–driven interventions—such as physical therapy, nutritional recommendations, and social support, among others—can reduce toxicity due to chemotherapy in adults with cancer aged 65 years and older, according to results from a randomized clinical trial presented as part of ASCO20...
Welcome to This Year’s Meeting: A Message From ASCO President Howard A. Burris III, MD, FACP, FASCO
Howard A. Burris III, MD, FACP, FASCO, President of ASCO, talks about what to expect from this year’s ASCO20 Virtual Scientific Program and its many offerings.
Adjuvant Osimertinib in Early-Stage EGFR-Positive NSCLC
Adjuvant osimertinib significantly improved disease-free survival compared with placebo in patients with stage IB to IIIA EGFR-mutated non–small cell lung cancer (NSCLC) who underwent complete resection of primary tumor and received chemotherapy if indicated. These results from the first interim...
Lymphoma: Many Questions, Too Few Answers
The successful treatment of malignant lymphoma has been one of the great achievements in medical oncology, but certainly more work is needed to define key biologic targets as well as molecular markers for a more accurate definition of prognosis following therapy. In day-to-day practice, unanswered...
ASCO as a Public Organization: No Longer Hiding Our Lamp Under a Basket
Like many professional organizations in the public sphere, ASCO regularly confronts policy issues. Because we are a large organization, and because we represent many constituencies, we are frequently called upon to offer our advice to the federal government. Our members must sometimes wonder where...
Why The ASCO Post?
It has been 5 years since ASCO has been part of a new publication, the last being the Journal of Oncology Practice (JOP). As the ASCO Board and leadership evaluated the publication mix we recognized there was a gap that needed to be filled. The Journal of Clinical Oncology (JCO), now 25 years old, ...
ESMO Breast 2020: Study Finds Physical Activity, Supportive Care to Relieve Cancer-Related Fatigue May Be Underutilized by Breast Cancer Survivors
Cancer-related fatigue is a prevalent and potentially persistent issue among breast cancer survivors. A study presented by Di Meglio et al at the ESMO Breast Cancer Virtual Meeting 2020 (Abstract 183O) has now shown that existing recommendations and proven strategies for reducing fatigue—which can...
Milestone Memories: Conquer Cancer Researcher Searches for Colorectal Cancer Cures
On her wedding day, a father—who happens to have colorectal cancer—walks his daughter down the aisle. His oncologist, Rona Yaeger, MD, of Memorial Sloan Kettering Cancer Center, helped him mark this milestone. Currently, patients with BRAF-mutant colorectal cancers face a poor prognosis. Dr....
Tips for First-Time Abstract Presenters
The fundamental goal of scientific meetings is to share knowledge and accelerate scientific advances. Investigators use different types of presentations to disseminate and share their valuable work with others in the field. This is an important aspect of promoting their scientific careers. These...
A Long Crusade Against Some of the World’s Most Virulent Diseases for Anthony S. Fauci, MD
The doctor-patient relationship, a time-honored tradition based on trust and cooperation, is critical for vulnerable patients, as they experience a heightened reliance on the physician’s competence, skills, and good will. That same trust is critical on the public health stage, when a nation is...
Jennifer C. King, PhD, Named CSO of GO2 Foundation
GO2 Foundation for Lung Cancer (GO2 Foundation) has promoted Jennifer C. King, PhD, to the role of Chief Scientific Officer. In her new position, Dr. King will be responsible for leading scientific and research priorities for a global patient advocacy group dedicated to saving, extending, and...
Brain Cancer Prepared Me for the Isolation and Uncertainty of the COVID-19 Pandemic
The symptoms of low-grade oligodendroglioma first appeared in the summer of 2003, when I was 12, but they were vague enough—mild headaches and occasional weird sensations on my right side—to ignore. In the fall, I tripped and fell during a game of rollerblade hockey with my classmates and started...
The Arc of Therapy—From Cure to Humbling Legacy
The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...
A Daughter of Immigrant Doctors, Nina Kadan-Lottick, MD, MSPH, Chose a Career in Pediatric Oncology
In 2003, Nina Kadan-Lottick, MD, MSPH, established the regional Yale HEROS multidisciplinary research and clinical program for long-term survivors of childhood cancer survivors, which is the first of its kind in Connecticut and one of the first in the United States. She intends the HEROS program to ...
Paul G. Marks, MD, Visionary Leader of Memorial Sloan Kettering Cancer Center, Dies at 93
In 1980, Paul G. Marks, MD, became the President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center (MSK), the oldest and largest private cancer center in the world. Over his 19-year reign, he is credited with setting MSK on a more scientific course by encouraging innovative...
What Have I Learned in More Than Half a Century in Cancer Medicine?
My journey in cancer medicine started in June 1968, when I traveled from Lebanon to New York to begin my fellowship in medical oncology at Memorial Sloan Kettering Cancer Center. Since then, and on a daily basis, I have been actively engaged in the treatment of patients with cancer and in cancer...
The Story of Three Patients With Leukemia
The human drama within the oncology world is a never-ending story of triumph, tragedy, and all of the valiant efforts and human emotions in between. The doctor-patient relationship in oncology is deeper and longer than in most medical specialties due to the life-and-death stakes at play after a...
Gynecologic Oncologist Describes His New Normal in a New York Hospital
During the COVID-19 pandemic, The ASCO Post will be interviewing oncologists on how they and their centers are dealing with the crisis. Here, we speak with Alexander Melamed, MD, MPH, a gynecologic oncologist and Assistant Professor of Obstetrics & Gynecology at NewYork-Presbyterian/Columbia...
Sleeping Well After Cancer: Patient-Centered Research for Treatment of Insomnia
Insomnia is a persistent sleep disorder that affects nearly 60% of people with cancer, diminishing their quality of life.1,2 Chronic insomnia disorder is defined by trouble falling asleep, staying asleep, or waking too early three times per week for 3 months or more.3 Standard care comprises...
Treating Patients With Leukemia During the COVID-19 Era at MD Anderson Cancer Center
As part of a series of interviews with cancer experts during the COVID-19 pandemic, The ASCO Post spoke with Hagop Kantarjian, MD, Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, about the impact of the pandemic on treatment of...
OneOncology Names Jeff Patton, MD, Chief Executive Officer
Jeff Patton, MD, has been named Chief Executive Officer of OneOncology, a national partnership of independent community oncologists. Dr. Patton has been Acting Chief Executive Officer and President of Physician Services since February. Dr. Patton will continue as Executive Chairman of the Board of ...
Despites Advances, Treatment-Related Sequelae Remain Problematic in Pediatric Neuro-oncology
The management of pediatric brain and spinal cord tumors is extremely complex, as are the survivorship issues in this highly vulnerable patient population. To shed light on the current clinical reality in this setting, The ASCO Post recently spoke with Katherine E. Warren, MD, an internationally...
Being Interviewed on Zoom? Here Are Some Professional Tips
You’ve agreed to be interviewed on Zoom. If you’re like most people, the technology itself isn’t a barrier. (And if it is, you can consult our step-by-step guide to using Zoom at https://bit.ly/2yxcTN0.) However, you might be less sure about what you can do to make the best impression (and the most ...
How the COVID-19 Pandemic Is Propelling the Delivery of Home Care for Patients With Cancer
In 2019, the Penn Center for Cancer Care Innovation at the University of Pennsylvania’s Abramson Cancer Center began planning a demonstration program, called Cancer Care at Home, to broaden the delivery of oncology treatments to patients in the home setting. The existing services offered by Penn...
Genetics May Soon Guide Targeted Treatment of Brain Metastases
Genetic mapping of brain metastases, in the laboratory of Priscilla Brastianos, MD, Director of the Central Nervous System Metastasis Center at Massachusetts General Hospital/Harvard Medical School, and Scott Carter, PhD, at the Harvard School of Public Health, is yielding findings that could...
ASCO’s President-Elect Aims to Ensure Equitable Cancer Care for Every Patient
The desire to pursue a career in medicine took root when Lori J. Pierce, MD, FASTRO, FASCO, was a young child visiting family in segregated Ahoskie, North Carolina. She witnessed firsthand the impact the town’s lone African American family physician had on the community. When it came time to...
Expert Point of View: Shannon N. Westin, MD, MPH, FACOG and Alexander Melamed, MD, MPH
Discussant of the abstract on the WEE1 inhibitor adavosertib, Shannon N. Westin, MD, MPH, FACOG, Associate Professor and clinical investigator at The University of Texas MD Anderson Cancer Center, called the interaction between P53 and WEE1 an “opportunity for synthetic lethality.” She continued:...
Expert Point of View: Pamela N. Munster, MD
Formal I-SPY 2 trial discussant, Pamela N. Munster, MD, Professor in the Department of Medicine, University of California, San Francisco, found the study promising but said confirmatory trials are needed. “What we know so far in preoperative therapy for breast cancer is that pathologic complete...
Overcoming the Challenges of Presenting the ASCO Annual Meeting During the COVID-19 Pandemic
As the worldwide cases of the coronavirus started to mount in February and March, medical societies and organizations monitoring the escalating COVID-19 pandemic and its impact on international and domestic travel made the difficult decision to postpone or cancel their scientific conferences. On...
United Against Cancer to Accelerate Progress for Patients
When I chose my Presidential theme for the 2020 ASCO Annual Meeting, “Unite and Conquer: Accelerating Progress Together,” in early 2019, I never imagined it would take on a new meaning 12 months later. The world is grappling with the COVID-19 pandemic, and, even as we practice social distancing, I...
